Orient
What does the care offer actually mean?
“Regenerative” points to a claim about repair or healing. Ask what would be done and what change the treatment is meant to bring.
The US drug review agency is the Food and Drug Administration (FDA).
Compare a broad label with a clear proposal
The broad label
“Regenerative care” names a goal, but leaves the treatment unnamed. Ask whether the offer involves a medicine or a procedure, and get its name.
The clear proposal
Ask for the product or procedure name, the condition it is meant to address, and how progress would be assessed.
Peptide is a description, not an answer
A peptide’s small parts link together like a short strand of beads; proteins contain those kinds of building parts too.
Insulin is a peptide medicine.
As of September 26, 2026, US rules treat an FDA-approved medicine differently from one made to order or an unapproved drug.
A made-to-order medicine can be legal even though it has no FDA approval.
The next page explains the checks for each kind. A label alone cannot tell you whether the offer meets those rules.
Turn your goal into a question
Write down what you would like to be able to do or feel differently. Bring that goal to the conversation.
- What could explain the problem I came in with?
- What would this treatment aim to change?
- What other options can we discuss?